Deaglan McHugh

8PUBLICATIONS
53CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursGlycoconjugates
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 18, 2026
Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer.

Jeffery C W Chang, Subhiksha Nandakumar, Konrad H Stopsack

|Jul 19, 2024
Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease.

Jack P Gleeson, Andrea Knezevic, Maria Bromberg

|Nov 10, 2023
Testicular cancer in 2023: Current status and recent progress.

Deaglan J McHugh, Jack P Gleeson, Darren R Feldman

|Sep 16, 2023
Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors.

Samuel A Funt, Andrea Knezevic, Kaamilah Wilson

|Mar 17, 2022
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.

Chung-Han Lee, Martin H Voss, Maria Isabel Carlo

|Jan 28, 2022
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.

Samuel A Funt, Michael Lattanzi, Karissa Whiting

Pageof 2

Frequent Collaborators

3 joint publications

Samuel A Funt

3 joint publications

Andrea Knezevic

3 joint publications

Robert J Motzer

3 joint publications

Darren R Feldman